Effectively characterizing therapeutic effects in early phase obesity research requires going beyond traditional endpoints. Integrating continuous glucose monitoring (CGM), electronic patient-reported outcomes (ePRO), and digital biomarkers enables a more complete and dynamic picture of treatment response. This mosaic effectively captures high-resolution metabolic profiles, real-world functional outcomes, and patient engagement in a unified framework. While challenges such as technology adoption, cross-platform data integration, and participant training must be proactively managed, digital integration is both feasible and high-value when paired with dedicated infrastructure and cross-functional collaboration.
Check out our poster for a closer look at operational strategies, endpoint alignment considerations, and best practices for bringing digital tools into your early phase obesity program.
Authors:
